

1020 Rec'd PCT/PTO 01 SEP 2005

Docket No.: RLL BUS

Serial No. 10/523,208

INFORMATION DISCLOSURE CITATION

Applicants: SILAMKOTI et al.

Filed: 1/27/2005

Group: 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JN	A1	3,176,019	3/30/1965	Campbell et al.	260	293.4	
JN	A2	4,183,857	1/15/1980	Kollmeyer	260	326.5	
JN	A3	5,281,601	1/25/1994	Cross et al.	514	320	
JN	A4	5,948,792	9/7/1999	Tsuchiya et al.	514	317	
JN	A5	6,130,232	10/10/2000	Mase et al.	514	318	
JN	A6	6,130,241	10/10/2000	Schulz	514	421	
JN	A7	6,174,900	1/16/2001	Okada et al.	514	317	
JN	A8	6,313,312	11/6/2001	Banks et al.	548	452	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
JN	B1	EP 0 325 571	7/26/1989	EPO	C07C	215/54		
JN	B2	EP 0 388 054	9/19/1990	EPO	C07D	207/08		
JN	B3	EP 0 801 067	10/15/1997	EPO	C07D	453/02		
JN	B4	GB 940,540	10/30/1963	UK	C07C			
JN	B5	JP 92921/1994	4/5/1994	Japan	C07C	237/20	Abstract	
JN	B6	JP 135958/1994	5/17/1994	Japan	C07D	333/16	Abstract	
JN	B7	WO 91/09013	6/27/1991	PCT	C07D	207/08		
JN	B8	WO 93/16018	8/19/1993	PCT	C05F	17/02		
JN	B9	WO 93/16048	8/19/1993	PCT	C07D	211/26		
JN	B10	WO 96/33973	10/31/1996	PCT	C07D	211/46	US 5,750,540 equivalent	
JN	B11	WO 97/45414	12/4/1997	PCT	C07D	211/58	Abstract	
JN	B12	WO 98/05641	2/12/1998	PCT	C07D	211/46	US 5,948,792 equivalent	
JN	B13	WO 98/29402	7/9/1998	PCT	C07D	311/20		

EXAMINER /Jason Nolan/

DATE CONSIDERED 12/18/2006


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-8US	Serial No.: 10/523,208
	Applicants: SILAMKOTI et al.	
	Filed: 1/27/2005	Group: 1626

JC20 Rec'd PCT/PTO 01 SEP 2005

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
JN	C1	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , 323(2):411-416 (1986)
JN	C2	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , 237:527-531 (1987)
JN	C3	Eglen et al., "Muscarinic receptor ligands and their theraputic potential", <i>Current Opinion in Chemical Biology</i> , 3:426-432 (1999)
JN	C4	Eglen et al., "Therapeutic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , 22(8):409-414 (2001)
JN	C5	Felder et al., "Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , 43(23):4333-4353 (2000)
JN	C6	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , 6:142-193 (2001)
JN	C7	Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , 22(5):215-219 (2001)
JN	C8	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , 41:691-721 (2001)
JN	C9	Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , 2(3):268-282
JN	C10	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , 55(Suppl. 5A):33-46 (2000)
JN	C11	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)
JN	C12	Sagara et al, "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M ₃ Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , 45(4):984-987 (2002)
JN	C13	Vogel's textbook, "Practical Organic Chemistry" 1046-1047 (5th Ed.)
JN	C14	Grover et al., "Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis", <i>Journal of Organic Chemistry</i> , 65:6283-6287 (2000)
JN	C15	Cheng and Prusoff, "Relationship between the inhibition constant (K ₁) and the concentration of inhibitor which causes 50 per cent inhibition (I ₅₀) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , 22:3099-3108 (1973)

EXAMINER	/Jason Nolan/	DATE CONSIDERED	12/18/2006
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE CITATION 	Docket No.: RLL-258US	Serial No.: 10/523,208
	Applicants: SILAMKOTI <i>et al.</i>	
	Filed: 1/27/2005	Group: 1626

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
JN	S1 C1	Dobson and Raphael, "729. The synthesis of DL-baikiaiin", <i>Journal of the Chemical Society</i> , 3642-3647 (1958)

EXAMINER	/Jason Nolan/	DATE CONSIDERED	12/18/2006
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>			